about
Possible future monoclonal antibody (mAb)-based therapy against arbovirus infectionsMapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display librariesDiverging Effects of Human Recombinant Anti-Hepatitis C Virus (HCV) Antibody Fragments Derived from a Single Patient on the Infectivity of a Vesicular Stomatitis Virus/HCV PseudotypeHepatitis C Virus (HCV) Infection May Elicit Neutralizing Antibodies Targeting Epitopes Conserved in All Viral GenotypesA human monoclonal antibody with neutralizing activity against highly divergent influenza subtypesNonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs.Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding siteThe era of molecular and other non-culture-based methods in diagnosis of sepsisA non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses.Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogensComparative evaluation of the Bruker Biotyper and Vitek MS matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry systems for identification of yeasts of medical importanceHeterosubtypic protection conferred by the human monoclonal antibody PN-SIA28 against influenza A virus lethal infections in miceInfluenza B-cells protective epitope characterization: a passkey for the rational design of new broad-range anti-influenza vaccines.Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein.A closer look at prion strains: characterization and important implications.Epitope mapping by epitope excision, hydrogen/deuterium exchange, and peptide-panning techniques combined with in silico analysis.HCV E2 core structures and mAbs: something is still missing.Virus-induced preferential antibody gene-usage and its importance in humoral autoimmunity.Adoptive T-cell therapy in the treatment of viral and opportunistic fungal infections.Novel therapeutic investigational strategies to treat severe and disseminated HSV infections suggested by a deeper understanding of in vitro virus entry processes.Potential impact of a microarray-based nucleic acid assay for rapid detection of Gram-negative bacteria and resistance markers in positive blood cultures.Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab.Chimeric antigen receptor (CAR)-redirected T cells: is there a place for them in infectious diseases?Cost-effectiveness of blood culture and a multiplex real-time PCR in hematological patients with suspected sepsis: an observational propensity score-matched study.Molecular mycological diagnosis and correct antimycotic treatmentsAnti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference.Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection.Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.Molecular diagnosis of polymicrobial sepsis.Potential role of the detection of enterobacterial DNA in blood for the management of neonatal necrotizing enterocolitis.Rational Dosing Strategies of Colistin: What About Resistance?Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs.Microbiological diagnosis of sepsis: the confounding effects of a "gold standard".Cloning and molecular characterization of a human recombinant IgG Fab binding to the Tat protein of human immunodeficiency virus type 1 (HIV-1) derived from the repertoire of a seronegative patient.Quantitation of Bacillus clausii in biological samples by real-time polymerase chain reaction.Rapid molecular identification of fungal pathogens in corneal samples from suspected keratomycosis cases.Antigen-Driven Evolution of B Lymphocytes in Coronary Atherosclerotic PlaquesAn outbreak caused by multidrug-resistant OXA-58-positive Acinetobacter baumannii in an intensive care unit in ItalyMicrobiome studies in the medical sciences and the need for closer multidisciplinary interplayHeparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the surface protein (spike) S1 receptor binding domain with heparin
P50
Q24289014-26A39A81-428A-4C2B-8497-4D39879020C5Q27469875-2088C9B8-4426-4E10-A7A2-86FA480ED976Q27472930-C2A8BCB9-0E56-4D08-87A8-2A5DEA2005E5Q27490450-D2197F52-4E54-470B-994D-40D6A544F9C0Q30410546-482ECC21-022D-488B-9FFF-1A576A36975EQ30711927-D8B21E21-DF74-4014-B330-D6A9A9936002Q33377024-52EC4A65-3450-4191-8DB2-951BD069D8FAQ33591270-3705B610-0B9A-421C-AAF9-9BFCEE2D6216Q34230088-37847FEB-1C05-46A0-A622-0F4D8EB99D36Q34401573-94B5C569-99C4-4CE3-9213-BBCA821AA39CQ34725107-627E986F-7D07-4647-B99F-749AB76674C5Q35385403-518EC407-3251-45B5-896B-DEB75A049561Q36432748-1B5E40E1-FD63-464D-A41F-202305F6B1A2Q36682313-0DA21396-D2DD-4846-8F11-1364455E42E2Q38077404-5F3B5D2B-0E7B-491F-8600-AFC85DC9CE6DQ38187027-C07BD333-97EA-4D04-8210-0D089BF7AC4AQ38244787-B7D599F3-2EBB-4E34-98A0-9EC419D40C41Q38412981-1EA0C2BE-7685-4F65-BD37-0AC7EAE798F2Q38417056-6F3C5A8B-8A2E-4729-85AE-02CB25F6552BQ38774799-E80C5327-B82D-476D-9E39-56D1265D3C0CQ38853173-B229499B-979D-411B-ABC1-7334F126AEA0Q40761630-03B79F08-A540-4A51-98D4-776F542FED8DQ41194064-F71D55E1-0325-4D26-87B5-A53A7317406BQ42217659-2236438E-6B1A-4156-BE87-2552EF46FD6CQ42593284-934F7766-BDA5-4ABB-A097-B321628958FFQ42983342-0CCFD946-573A-4441-A220-550C21FA58D8Q42987364-959D2D1F-146E-4DE3-93A1-CC85462F3717Q43030792-0A475C28-6E6E-4262-A8CE-AABACA7ED890Q43146546-ED19DEF0-CD0C-4220-B079-CA4ADB0E49EDQ44106479-6CD9C572-3D38-4D2C-9A12-3A4FFB80476AQ44461793-EE12AB2D-1080-42BC-835C-26D72E29C652Q45227077-4502AAC5-C96C-48A3-8599-F8D59D65C6B9Q45304890-A68D7362-A98D-4E67-8294-60532C2A2696Q45423570-20015F6B-5801-4BB4-876F-16EC34FB8709Q46828466-46672894-6BF6-49F9-8DF3-35475C5958F4Q54577253-011D392C-840A-47AC-81C1-DA390E0EF3A8Q58228906-5DE60ABC-F3F0-4A75-BBDF-26083F745884Q80155561-5CD187CE-035E-46EC-9A52-D35A398BA5F8Q89531763-B1EA024F-FE1F-4FB1-8F22-B97F6E6E4956Q95628510-C79DC193-8D5C-46AA-A4BC-AE06A36A44D9
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nicasio Mancini
@ast
Nicasio Mancini
@en
Nicasio Mancini
@es
Nicasio Mancini
@nl
type
label
Nicasio Mancini
@ast
Nicasio Mancini
@en
Nicasio Mancini
@es
Nicasio Mancini
@nl
prefLabel
Nicasio Mancini
@ast
Nicasio Mancini
@en
Nicasio Mancini
@es
Nicasio Mancini
@nl
P106
P1153
7004143970
P21
P31
P496
0000-0003-0637-0910